- Exchange: SIX Swiss Ex
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Cytos Biotechnology AG
+ Add to WatchlistCYTN:SW
4.03 CHF 0.03 0.74%As of 11:43:33 ET on 05/17/2013.
Snapshot for Cytos Biotechnology AG (CYTN)
| Open: | 4.07 | Day's Range: | 4.03 - 4.09 | Volume: | 7,614 |
|---|---|---|---|---|---|
| Previous Close: | 4.06 | 52wk Range: | 1.99 - 6.15 | 1-Yr Rtn: | +83.18% |
Key Statistics for CYTN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SMI | - |
| Earnings Per Share (CHF) (ttm) | -1.1100 |
| Est. EPS (CHF) (12/2013) | -0.9100 |
| Est. PEG Ratio | - |
| Market Cap (M CHF) | 90.32 |
| Shares Outstanding (M) | 22.41 |
| 30 Day Average Volume | 10,907 |
| Price/Book (mrq) | 17.9797 |
| Price/Sale (ttm) | 50.5504 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/25/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CYTN
Company Profile & Key Executives for CYTN
Cytos Biotechnology AG develops and produces biopharmaceuticals. The Company produces vaccines that immunize the patient against disease related proteins. This instructs the immune system to produce antibodies to reverse or prevent disease progression. Cytos develops treatments for immunology and inflammation disorders, cancer and cardiovascular, nervous system, and infectious diseases.
| Christian ItinChairman/CEO | Harry WeltenExec VP/CFO |
| Matthias AlderExec VP:Corporate Development | Cheryl LassenVP:Clinical Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CYTN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page